Detail akcie Ionis Pharmaceutcls online

Business Summary: Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Ionis Pharmaceuticals Inc revenues increased 55% to $740.4M. Net loss decreased 57% to $152M. Revenues reflect Collaborative agreement revenue increase of 75% to $413.4M. Lower net loss reflects Ionis operations segment loss decrease of 54% to $167.2M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.38 to -$0.95.